All In Biotech

Drug Trial Radar · NCT03026907

Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema

Efficacy of Oral Alitretinoin Versus Oral Azathioprine in Patients With Severe Chronic Non-hyperkeratotic Hand Eczema. A Randomized Prospective Open-label Trial With Blinded Outcome Assessment

Last checked: Nov 20, 2026Latest source record: May 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

116

Planned (sponsor's estimate)

Start

May 2016

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of alitretinoin and azathioprine in the treatment of patients with severe chronic non-hyperkeratotic hand eczema.

Conditions

  • Hand Eczema

Interventions

  • AlitretinoinDrug

    Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.

  • AzathioprineDrug

    Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to treatment/hand eczema severity (Photoguide)Time frame: 24 weeks (end of treatment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.